Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 56.6 Cr.
- Current Price ₹ 22.6
- High / Low ₹ 41.1 / 16.0
- Stock P/E 435
- Book Value ₹ 24.1
- Dividend Yield 0.00 %
- ROCE 5.74 %
- ROE 1.72 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.94 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -22.5%
- The company has delivered a poor sales growth of 0.50% over past five years.
- Promoter holding is low: 27.1%
- Company has a low return on equity of -0.42% over last 3 years.
- Promoters have pledged 47.8% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9.87 | 14.21 | 22.60 | 30.93 | 46.68 | 51.78 | 65.90 | 62.44 | 57.05 | 72.38 | 64.10 | 67.56 | 63.33 | |
9.35 | 12.73 | 19.05 | 26.02 | 39.08 | 41.68 | 52.93 | 54.54 | 49.34 | 62.86 | 59.06 | 58.49 | 55.94 | |
Operating Profit | 0.52 | 1.48 | 3.55 | 4.91 | 7.60 | 10.10 | 12.97 | 7.90 | 7.71 | 9.52 | 5.04 | 9.07 | 7.39 |
OPM % | 5.27% | 10.42% | 15.71% | 15.87% | 16.28% | 19.51% | 19.68% | 12.65% | 13.51% | 13.15% | 7.86% | 13.43% | 11.67% |
0.00 | 0.00 | 0.14 | 0.21 | 0.47 | 0.07 | 0.18 | 0.95 | 0.72 | 0.00 | 0.40 | 0.56 | 1.06 | |
Interest | 0.00 | 0.00 | 1.25 | 1.48 | 3.98 | 5.14 | 5.94 | 5.52 | 5.90 | 6.40 | 5.25 | 4.79 | 4.21 |
Depreciation | 0.00 | 0.00 | 0.16 | 0.88 | 1.93 | 1.95 | 1.95 | 2.39 | 2.45 | 2.45 | 2.57 | 3.64 | 3.67 |
Profit before tax | 0.52 | 1.48 | 2.28 | 2.76 | 2.16 | 3.08 | 5.26 | 0.94 | 0.08 | 0.67 | -2.38 | 1.20 | 0.57 |
Tax % | 30.77% | 32.43% | 32.46% | 32.25% | 28.70% | 24.68% | 23.95% | 30.85% | 187.50% | 50.75% | 4.20% | 10.00% | |
0.36 | 1.00 | 1.54 | 1.86 | 1.55 | 2.31 | 4.00 | 0.66 | -0.07 | 0.33 | -2.28 | 1.08 | 0.12 | |
EPS in Rs | 360.00 | 250.00 | 154.00 | 186.00 | 110.71 | 165.00 | 285.71 | 0.38 | -0.03 | 0.14 | -0.91 | 0.43 | 0.05 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 1% |
3 Years: | 6% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | -23% |
3 Years: | 112% |
TTM: | 168% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 20% |
1 Year: | -38% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 0% |
3 Years: | 0% |
Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.10 | 0.40 | 1.00 | 1.00 | 1.40 | 1.40 | 1.40 | 17.14 | 23.36 | 23.36 | 25.00 | 25.00 | 25.00 |
Reserves | 1.53 | 3.23 | 5.37 | 7.23 | 9.58 | 11.89 | 16.34 | 4.56 | 36.19 | 36.51 | 35.35 | 36.43 | 35.20 |
3.83 | 9.06 | 15.96 | 32.00 | 31.06 | 39.68 | 50.41 | 48.66 | 51.22 | 49.30 | 43.08 | 42.72 | 40.29 | |
2.12 | 3.82 | 3.79 | 6.09 | 14.78 | 8.31 | 8.42 | 21.66 | 23.92 | 25.47 | 36.36 | 36.48 | 40.60 | |
Total Liabilities | 7.58 | 16.51 | 26.12 | 46.32 | 56.82 | 61.28 | 76.57 | 92.02 | 134.69 | 134.64 | 139.79 | 140.63 | 141.09 |
0.42 | 1.23 | 2.50 | 19.40 | 18.14 | 21.48 | 20.00 | 23.48 | 20.78 | 18.73 | 32.82 | 29.42 | 27.67 | |
CWIP | 2.12 | 6.79 | 9.71 | 4.78 | 5.38 | 3.69 | 6.56 | 6.37 | 24.80 | 25.71 | 13.00 | 13.89 | 14.30 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 |
5.04 | 8.49 | 13.91 | 22.14 | 33.30 | 36.11 | 50.01 | 62.17 | 82.02 | 83.11 | 86.88 | 90.23 | 92.03 | |
Total Assets | 7.58 | 16.51 | 26.12 | 46.32 | 56.82 | 61.28 | 76.57 | 92.02 | 134.69 | 134.64 | 139.79 | 140.63 | 141.09 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 9.89 | 6.03 | 7.74 | 12.80 | -9.24 | 5.46 | 5.51 | 2.15 | |
0.00 | 0.00 | 0.00 | 0.00 | -5.08 | -4.02 | -2.69 | -8.32 | -25.16 | -1.20 | -3.85 | -1.08 | |
0.00 | 0.00 | 0.00 | 0.00 | -4.74 | -1.51 | -5.53 | -2.74 | 35.09 | -5.07 | -2.65 | -1.17 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.50 | -0.48 | 1.74 | 0.69 | -0.81 | -0.99 | -0.10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82.84 | 79.37 | 121.29 | 115.88 | 95.47 | 96.85 | 141.62 | 129.89 | 127.64 | 93.49 | 103.98 | 127.18 |
Inventory Days | 169.27 | 158.62 | 137.27 | 127.72 | 160.45 | 144.03 | 267.18 | 260.38 | 429.96 | 410.52 | ||
Days Payable | 60.32 | 70.56 | 122.04 | 20.77 | 53.01 | 143.67 | 216.64 | 179.36 | 363.86 | 278.67 | ||
Cash Conversion Cycle | 82.84 | 79.37 | 230.24 | 203.94 | 110.70 | 203.81 | 249.07 | 130.25 | 178.17 | 174.52 | 170.08 | 259.03 |
Working Capital Days | 116.49 | 124.58 | 158.60 | 165.45 | 107.75 | 164.95 | 199.23 | 158.24 | 141.52 | 120.57 | 192.41 | 210.32 |
ROCE % | 11.97% | 16.31% | 20.16% | 13.55% | 14.93% | 17.30% | 18.49% | 9.39% | 6.68% | 6.61% | 2.77% | 5.74% |
Documents
Announcements
- Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31St March 2024. 30 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr
- Submission Of Certificate Of Compliance Report For The Year Ended On 31St March, 2024 Under Regulation 40(9) & (10) Of SEBI (LODR) Regulations, 2015. 30 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Apr - Certificate under Regulation 74(5) of SEBI(DP) Regulations 2018 for the quarter ended on 31st March 2024
- Quarterly Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount On Loans From Banks / Financial Institutions And Unlisted Debt Securities 6 Apr
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.